YU30392A - PYRIDAZINONE ACETIC ACID - Google Patents

PYRIDAZINONE ACETIC ACID

Info

Publication number
YU30392A
YU30392A YU30392A YU30392A YU30392A YU 30392 A YU30392 A YU 30392A YU 30392 A YU30392 A YU 30392A YU 30392 A YU30392 A YU 30392A YU 30392 A YU30392 A YU 30392A
Authority
YU
Yugoslavia
Prior art keywords
group
phenyl
acetic acid
oxadiazol
pyridazinone acetic
Prior art date
Application number
YU30392A
Other languages
Serbo-Croatian (sh)
Inventor
L. Mylari Banavara
W.J. Zembrowski
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU30392A publication Critical patent/YU30392A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

PIRIDAZINON SIRĆETNE KISELINE, opisane su piridazinon sirćetne kiseline, jedinjenja koja poseduju osobine inhibiranja aktivnosti aldoza reduktaze, čija je formula u kojoj X je CH2, CH2CH2' -CHCH3, ; Y je O ili S; R1 je opciono supstituisan fenil, benzotiazol-2-il, benzoksazol-2-il, benzofuran-2-il, benzotiofen-2-il, tiazolopiridin-2-il, ok-sazolopiridin-2-il, 3-fenil-1,2,4-oksadiazol-5-il, i 5-fenil-1,2,4-ok-sadiazol-3-il pri čemu pomenute supstituisane grupe su supstituisane sa jednim ili više i poželjno sa dva supstituenta koji su nezavisno odabrani iz grupe koju sačinjavaju fluor, hlor, brom, metil, i tri-fluorometil; R2 i R3 su nezavisno odabrani iz grupe koju sačinjavaju vodonik, fluor, hlor, brom, (C1-C4)alkil, metil (C1-C4) alkiltio, (C1-C4) alkoksi i trifluorometil ili R2 i R3 uzeti zajedno sa ugljenicima za koji su vezani obrazuju grupu W, a W je gde p je 1 ili 2 i U1 i U2 su nezavisno CH2, O ili S; pod uslovom što oba U1 i U2 nisu O ili S; R4 je vodonik ili prolek grupa; ili njihove farmaceutski prihvatljive soli.PYRIDAZINONE ACETIC ACIDS, described as pyridazinone acetic acid, compounds having aldose reductase inhibiting properties, the formula of which is X is CH2, CH2CH2 '-CHCH3,; Y is O or S; R 1 is optionally substituted phenyl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl-1, 2,4-Oxadiazol-5-yl, and 5-phenyl-1,2,4-oxadiazol-3-yl wherein said substituted groups are substituted with one or more and preferably with two substituents independently selected from the group consisting of fluorine, chlorine, bromine, methyl, and tri-fluoromethyl; R 2 and R 3 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, (C 1 -C 4) alkyl, methyl (C 1 -C 4) alkylthio, (C 1 -C 4) alkoxy and trifluoromethyl, or R 2 and R 3 taken together with carbons for which are attached to form a group W, and W is wherein p is 1 or 2 and U1 and U2 are independently CH2, O or S; provided that both U1 and U2 are not O or S; R4 is a hydrogen or prodrug group; or a pharmaceutically acceptable salt thereof.

YU30392A 1991-03-28 1992-03-26 PYRIDAZINONE ACETIC ACID YU30392A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
YU30392A true YU30392A (en) 1994-11-15

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
YU30392A YU30392A (en) 1991-03-28 1992-03-26 PYRIDAZINONE ACETIC ACID

Country Status (19)

Country Link
EP (1) EP0582643A1 (en)
JP (1) JPH06500793A (en)
CN (1) CN1065269A (en)
AU (1) AU658887B2 (en)
BR (1) BR9205810A (en)
CA (1) CA2107104A1 (en)
CZ (1) CZ387092A3 (en)
DE (1) DE9290035U1 (en)
FI (1) FI934222A (en)
HU (1) HUT67836A (en)
IE (1) IE920979A1 (en)
IL (1) IL101325A0 (en)
MX (1) MX9201414A (en)
NZ (1) NZ242152A (en)
PT (1) PT100301A (en)
TW (1) TW207998B (en)
WO (1) WO1992017446A2 (en)
YU (1) YU30392A (en)
ZA (1) ZA922238B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
SE0100873D0 (en) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
ATE348100T1 (en) 2001-03-30 2007-01-15 Pfizer Prod Inc INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS.
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (en) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 Hyperuricemia medicine composition and medicine for treating hyperuricemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (en) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド Process for producing oxophthalazinyl acetic acid having heterocyclic side chain such as benzothiazole
FR2647676A1 (en) * 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors

Also Published As

Publication number Publication date
CN1065269A (en) 1992-10-14
JPH06500793A (en) 1994-01-27
BR9205810A (en) 1994-06-28
CA2107104A1 (en) 1992-09-29
NZ242152A (en) 1994-07-26
FI934222A0 (en) 1993-09-27
IE920979A1 (en) 1992-10-07
HUT67836A (en) 1995-05-29
CZ387092A3 (en) 1994-02-16
EP0582643A1 (en) 1994-02-16
FI934222A (en) 1993-09-27
WO1992017446A2 (en) 1992-10-15
AU1779692A (en) 1992-11-02
AU658887B2 (en) 1995-05-04
DE9290035U1 (en) 1993-11-18
MX9201414A (en) 1992-10-01
HU9302728D0 (en) 1993-12-28
TW207998B (en) 1993-06-21
ZA922238B (en) 1993-09-27
WO1992017446A3 (en) 1992-11-26
IL101325A0 (en) 1992-11-15
PT100301A (en) 1993-06-30

Similar Documents

Publication Publication Date Title
RS49779B (en) Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL104614A (en) 4-benzoylisoxazole derivatives and herbicidal compositions comprising them
CA2298033A1 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
MY149463A (en) Novel compounds
YU7092A (en) HERBICIDES
ME00411B (en) Novel compounds having inhibitory activity against sodium-dependant transporter
AR015419A1 (en) COMPOUNDS DERIVED FROM HYDROXAMIC ARYLOXIALRILSULPHONYLAMINE ACIDS, COMPOSITIONS AND USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES.
FI963238A0 (en) Heteroaromatic oxazole compounds and their use
ATE88182T1 (en) ANTIDEPRESSIVE N-SUBSTITUTED NICOTINAMIDE COMPOUNDS.
YU49122B (en) Substituted benzylaminopiperidine compounds
RS54453B1 (en) Halogenated benzamide derivatives
PE20050145A1 (en) DIHYDROQUINAZOLINES SUBSTITUTE AS ANTIVIRAL AGENTS
ES521125A0 (en) PROCEDURE FOR PREPARING SPIRAL (PIPERIDINE-OXOBENZOXAZINES) SUBSTITUTED IN POSITION 1 ANTI-HYPERTENSIVE.
YU30392A (en) PYRIDAZINONE ACETIC ACID
NO175254C (en) Analogous procedure for the preparation of therapeutically active derivatives of N-sulfonylindoline
RS49965B (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
CO5080801A1 (en) PROTEASE INHIBITORS
EA200201255A1 (en) NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
BR9815017A (en) 5- (2-Imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha-adrenoreceptor agonists with improved metabolic stability
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
YU52498A (en) USE OF 2-ARYLBENZEN (b) THIOPHENE FOR MEDICAMENT PREPARATION
RS50505B (en) Carbamate compounds for use in preventing or treating anxiety disorders
RS50439B (en) Pyridazinyl phenyl hydrazones useful against congestive heart failure
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
ES8201962A1 (en) Novel 1,1,3,5-substituted biuret compound and a pharmaceutical composition containing the same